GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (FRA:V7B) » Definitions » EV-to-FCF

Assembly Biosciences (FRA:V7B) EV-to-FCF : -1.03 (As of May. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Assembly Biosciences EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Assembly Biosciences's Enterprise Value is €-25.72 Mil. Assembly Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €25.07 Mil. Therefore, Assembly Biosciences's EV-to-FCF for today is -1.03.

The historical rank and industry rank for Assembly Biosciences's EV-to-FCF or its related term are showing as below:

FRA:V7B' s EV-to-FCF Range Over the Past 10 Years
Min: -17.57   Med: 0.23   Max: 1610.41
Current: -1

During the past 13 years, the highest EV-to-FCF of Assembly Biosciences was 1610.41. The lowest was -17.57. And the median was 0.23.

FRA:V7B's EV-to-FCF is ranked better than
98.64% of 369 companies
in the Biotechnology industry
Industry Median: 8.9 vs FRA:V7B: -1.00

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-28), Assembly Biosciences's stock price is €13.65. Assembly Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-9.703. Therefore, Assembly Biosciences's PE Ratio for today is At Loss.


Assembly Biosciences EV-to-FCF Historical Data

The historical data trend for Assembly Biosciences's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences EV-to-FCF Chart

Assembly Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.72 0.01 0.29 0.29 -3.29

Assembly Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 -0.03 -0.02 -3.29 -1.37

Competitive Comparison of Assembly Biosciences's EV-to-FCF

For the Biotechnology subindustry, Assembly Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Assembly Biosciences's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's EV-to-FCF falls into.



Assembly Biosciences EV-to-FCF Calculation

Assembly Biosciences's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-25.721/25.071
=-1.03

Assembly Biosciences's current Enterprise Value is €-25.72 Mil.
Assembly Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €25.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Assembly Biosciences  (FRA:V7B) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Assembly Biosciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=13.65/-9.703
=At Loss

Assembly Biosciences's share price for today is €13.65.
Assembly Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.703.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Assembly Biosciences EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Assembly Biosciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Assembly Biosciences (FRA:V7B) Business Description

Traded in Other Exchanges
Address
331 Oyster Point Boulevard, Fourth Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, that are designed to restore health to a dysbiotic microbiome. The firm's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Its program targets high-recurrence genital herpes associated with herpes simplex virus type 2 (HSV-2) infection and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including hepatitis delta virus (HDV) and transplant-related herpesviruses.

Assembly Biosciences (FRA:V7B) Headlines

No Headlines